Rosen Law Firm filed a securities fraud class action against Zoetis Inc. on May 28, alleging the company misled investors about weakening demand for its flagship products. Zoetis shares fell 21.5% on May 7 after reporting significant deterioration in its Companion Animal business.
Rosen Law Firm filed a securities fraud class action against Zoetis Inc. on May 28, alleging the animal health company misled investors about weakening demand for its flagship products during an 18-month period ending May 6, 2026.
"Zoetis failed to disclose that veterinarian prescription growth and adoption of Librela, a canine pain treatment, were sharply weakening as clinicians became more cautious following FDA safety warnings concerning serious neurological complications in dogs," the complaint said. The lawsuit also cited three additional product lines facing competitive pressure.
Zoetis shares fell 21.5% to $87.31 on May 7 after the company reported first-quarter 2026 results showing significant deterioration across its core Companion Animal business and sharply reduced its full-year guidance. The single-day drop erased about $12 billion in market value from the $111.22 close the prior session. The stock has since traded near that level, reflecting lingering uncertainty about the company's growth trajectory.
The lawsuit covers investors who bought Zoetis securities between Jan. 14, 2025, and May 6, 2026. Lead plaintiff filings are due by July 27, 2026. The complaint alleges that Simparica Trio lost significant market share to a lower-priced competing canine parasiticide with broader indicated use in a slowing overall market, while dermatology products Apoquel and Cytopoint lost substantial share to a newly launched competing canine treatment.
The truth behind the alleged misrepresentations emerged over four disclosures from Aug. 5, 2025, to May 7, 2026, according to the complaint. Each disclosure revealed incremental deterioration in Zoetis's product portfolio, culminating in the first-quarter earnings miss that triggered the steepest single-day decline in the company's recent history.
Zoetis, which develops and manufactures vaccines, medicines, diagnostics, and digital solutions for companion animals and livestock, had positioned its pet care portfolio as a durable growth driver. The allegations now threaten that narrative and expose the company to potential financial liability. The case is pending in the U.S. District Court.
The allegations strike at the heart of Zoetis's growth narrative, which had relied on its companion animal portfolio as a durable revenue engine. Zoetis's next quarterly report, due in August, will test whether the competitive pressures have stabilized or deepened further.
This article is for informational purposes only and does not constitute investment advice.
